SETH LERNER to Thymidine Kinase
This is a "connection" page, showing publications SETH LERNER has written about Thymidine Kinase.
Connection Strength
0.463
-
Combination of adenovirus-mediated thymidine kinase gene therapy with cytotoxic chemotherapy in bladder cancer in vitro. Urol Oncol. 2003 May-Jun; 21(3):197-205.
Score: 0.214
-
Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Ann Oncol. 2001 May; 12(5):621-5.
Score: 0.046
-
In vivo adenovirus-mediated suicide gene therapy of orthotopic bladder cancer. Mol Ther. 2000 Sep; 2(3):211-7.
Score: 0.044
-
Adenovirus-mediated suicide gene therapy for bladder cancer: comparison of the cytomegalovirus- and Rous sarcoma virus-promoter. Anticancer Res. 2000 Sep-Oct; 20(5A):2811-6.
Score: 0.044
-
Adenovirus-mediated combination suicide and cytokine gene therapy for bladder cancer. Anticancer Res. 2000 May-Jun; 20(3A):1359-65.
Score: 0.043
-
Current status of gene therapy for prostate and bladder cancer. Int J Urol. 1997 Sep; 4(5):435-40.
Score: 0.036
-
Adenovirus-mediated suicide gene therapy for experimental bladder cancer. Urology. 1997 Feb; 49(2):173-80.
Score: 0.035